Risk-adapted use of intravesical immunotherapy.
Braasch
Matthew R
MR
Department of Urology, University of Iowa, Iowa City, IA 52242-1089, USA.
Böhle
Andreas
A
O'Donnell
Michael A
MA
D000283:Administration, Intravesical; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D012307:Risk Factors; D017211:Treatment Failure; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D016898:Interferon-alpha